Current Report Filing (8-k)
22 April 2022 - 6:42AM
Edgar (US Regulatory)
false 0001762303 0001762303 2022-04-19 2022-04-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 19, 2022
Avita Medical, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-39059 |
|
85-1021707 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
| 28159 Avenue Stanford, Suite 220, Valencia, CA 91355 |
|
661.367.9170 |
| (Address of principal executive offices, including Zip Code) |
|
(Registrant’s telephone number, including area code) |
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
RCEL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On April 19, 2022, Non-Executive Director Louis Drapeau notified the Chair of the Board of Directors of AVITA Medical, Inc. (the “Company”) that due to changed personal circumstances, Mr. Drapeau is resigning from the Board of Directors. Such resignation is effective April 29, 2022. Mr. Drapeau’s pending resignation did not result from any disagreements between himself and the Company on any matter concerning its operations, policies, or practices. Non-Executive Director James Corbett will assume Mr. Drapeau’s former role as Chair of the Audit Committee.
On April 21, 2022, the Company issued a press release announcing the resignation of Mr. Drapeau as described in Item 5.02 above. A copy of the press release, which is attached hereto as Exhibit 99.1, is furnished pursuant to Items 8.01 and 9.01.
The information in this Item 8.01 and Item 9.01 below is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 21, 2022
|
|
|
| AVITA MEDICAL, INC. |
|
|
| By: |
|
/s/ Donna Shiroma |
| Name: |
|
Donna Shiroma |
| Title: |
|
General Counsel |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024
